HR+/HER2-NEGATIVE BREAST CANCER
Clinical trials for HR+/HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Triple-Drug combo aims to tame breast cancer and its side effects
Disease control Recruiting nowThis study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the triple combination is safe and can reduce severe blood sugar spikes, a common side effect of current therapies. About 52 …
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: SynDevRx, Inc. • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New pill shows promise for hard-to-treat breast cancer
Disease control Recruiting nowThis early-stage trial tests a new daily pill, TOS-358, in women with advanced HR+ HER2- breast cancer that has a specific gene change (PIK3CA). The study aims to find the best dose and see if the drug is safe and effective, both alone and with standard treatments. About 241 part…
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Totus Medicines • Aim: Disease control
Last updated May 26, 2026 08:58 UTC